[Federal Register Volume 84, Number 104 (Thursday, May 30, 2019)]
[Notices]
[Pages 25057-25059]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-11220]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[60Day-19-19AWX; Docket No. CDC-2019-0042]
Proposed Data Collection Submitted for Public Comment and
Recommendations
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice with comment period.
-----------------------------------------------------------------------
SUMMARY: The Centers for Disease Control and Prevention (CDC), as part
of its continuing effort to reduce public burden and maximize the
utility of government information, invites the general public and other
Federal agencies the opportunity to comment on a proposed and/or
continuing information collection, as required by the Paperwork
Reduction Act of 1995. This notice invites comment on a proposed
information collection project titled WISEWOMAN National Program
Evaluation. The goal of the study is to assess the implementation of
the WISEWOMAN program under the current cooperative agreement and
measure the effect of the program on individual-, organizational-, and
community-level outcomes.
DATES: CDC must receive written comments on or before July 29, 2019.
ADDRESSES: You may submit comments, identified by Docket No. CDC-2019-
0042 by any of the following methods:
Federal eRulemaking Portal: Regulations.gov. Follow the
instructions for submitting comments.
Mail: Jeffrey M. Zirger, Information Collection Review
Office, Centers for Disease Control and Prevention, 1600 Clifton Road
NE, MS-D74, Atlanta, Georgia 30329.
Instructions: All submissions received must include the agency name
and Docket Number. CDC will post, without change, all relevant comments
to Regulations.gov.
Please note: Submit all comments through the Federal
eRulemaking portal (regulations.gov) or by U.S. mail to the address
listed above.
FOR FURTHER INFORMATION CONTACT: To request more information on the
proposed project or to obtain a copy of
[[Page 25058]]
the information collection plan and instruments, contact Jeffrey M.
Zirger, Information Collection Review Office, Centers for Disease
Control and Prevention, 1600 Clifton Road NE, MS-D74, Atlanta, Georgia
30329; phone: 404-639-7570; Email: [email protected].
SUPPLEMENTARY INFORMATION: Under the Paperwork Reduction Act of 1995
(PRA) (44 U.S.C. 3501-3520), Federal agencies must obtain approval from
the Office of Management and Budget (OMB) for each collection of
information they conduct or sponsor. In addition, the PRA also requires
Federal agencies to provide a 60-day notice in the Federal Register
concerning each proposed collection of information, including each new
proposed collection, each proposed extension of existing collection of
information, and each reinstatement of previously approved information
collection before submitting the collection to the OMB for approval. To
comply with this requirement, we are publishing this notice of a
proposed data collection as described below.
The OMB is particularly interested in comments that will help:
1. Evaluate whether the proposed collection of information is
necessary for the proper performance of the functions of the agency,
including whether the information will have practical utility;
2. Evaluate the accuracy of the agency's estimate of the burden of
the proposed collection of information, including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and clarity of the information to
be collected; and
4. Minimize the burden of the collection of information on those
who are to respond, including through the use of appropriate automated,
electronic, mechanical, or other technological collection techniques or
other forms of information technology, e.g., permitting electronic
submissions of responses.
5. Assess information collection costs.
Proposed Project
WISEWOMAN National Program Evaluation--New--National Center for
Chronic Disease Prevention and Health Promotion (NCCDPHP), Centers for
Disease Control and Prevention (CDC).
Background and Brief Description
The CDC has supported the WISEWOMAN (Well-Integrated Screening and
Evaluation for Women Across the Nation) program since 1995. The
WISEWOMAN program is designed to serve low-income women ages 40-64 who
have elevated risk factors for cardiovascular disease (CVD) and have no
health insurance, or are underinsured for medical and preventive care
services. Through the WISEWOMAN program, women have access to screening
services for selected CVD risk factors such as elevated blood
cholesterol, hypertension, and abnormal blood glucose levels; referrals
to heathy behavior support programs; and referrals to medical care.
WISEWOMAN participants must be co-enrolled in the CDC-sponsored
National Breast and Cervical Cancer Early Detection Program (NBCCEDP).
The WISEWOMAN program is administered through cooperative
agreements with state, territorial, or tribal health departments. Each
WISEWOMAN recipient submits to CDC an annual progress report that
describes program objectives and activities, and semi-annual data
reports (known as minimum data elements, or MDE) on the screening,
assessment, and healthy behavior support services offered to women who
participate in the program. Participant-level MDE are de-identified
prior to transmission to CDC.
In 2018, CDC released the fifth funding opportunity announcement
(FOA) for the WISEWOMAN program (DP18-1816), which resulted in five-
year cooperative agreements with 24 state, territorial, and tribal
health departments, including 6 new and 18 continuing awardees from the
previous NOFO. Key program elements were retained (e.g., provision of
screening services, promotion of healthy lifestyle behaviors, and
linkage to healthy behavior support services and community based
resources), but a number of changes were incorporated into the program
at that time. The current FOA reflects increased emphasis on three
strategies to reduce CVD risk and support hypertension control and
management, including: (1) Tracking and monitoring clinical measures,
(2) implementing team-based care, and (3) linking community resources
and clinical services to support care coordination, self-management,
and lifestyle change.
CDC seeks to conduct a one-time, multi-component evaluation to
assess the effectiveness of the program on individual-, organizational-
, and community-level outcomes. The in-depth assessment is designed to
complement the routine progress and MDE information already being
collected from WISEWOMAN program recipients. The new data collection
will focus on obtaining qualitative and quantitative information at the
organizational and community levels about process and procedures
implemented, and barriers, facilitators, and other contextual factors
that affect program implementation and participant outcomes. Data
collection activities will include a Program Survey with all WISEWOMAN
awardee programs, administered in the second and fourth program years,
and a one-time site visit to each recipient spread across the three-
year data collection effort. During site visits, semi-structured
interviews will be conducted with WISEWOMAN staff members and staff at
partner organizations, such as clinical providers and community-based
resource providers, who are positioned to provide a variety of
perspectives on program implementation.
OMB approval is requested for three years. Participation is
voluntary and there are no costs to respondents other than their time.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of Average burden
Type of respondents Form name Number of responses per per response Total burden
respondents respondent (in hours) (in hours)
----------------------------------------------------------------------------------------------------------------
WISEWOMAN Recipient Program survey.. 18 1 1 16
Administrators.
Site Visit 8 1 90/60 12
Discussion
Guide.
Innovation Site 2 1 45/60 2
Visit
Discussion
Guide.
Recipient partners............ Site Visit 16 1 1 16
Discussion
Guide.
Innovation Site 2 1 45/60 2
Visit
Discussion
Guide.
[[Page 25059]]
Healthy behavior support staff Site Visit 16 1 1 16
Discussion
Guide.
Innovation Site 2 1 45/60 2
Visit
Discussion
Guide.
Clinical providers............ Site Visit 16 1 1 16
Discussion
Guide.
Innovation Site 2 1 45/60 2
Visit
Discussion
Guide.
---------------------------------------------------------------
Total..................... ................ .............. .............. .............. 84
----------------------------------------------------------------------------------------------------------------
Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Scientific
Integrity, Office of Science, Centers for Disease Control and
Prevention.
[FR Doc. 2019-11220 Filed 5-29-19; 8:45 am]
BILLING CODE 4163-18-P